Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -43.43
- Piotroski Score 3.00
- Grade Buy
- Symbol (CRIS)
- Company Curis, Inc.
- Price $4.08
- Changes Percentage (-0.49%)
- Change -$0.02
- Day Low $3.82
- Day High $4.21
- Year High $17.49
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$8.62
- Trailing P/E Ratio -1.03
- Forward P/E Ratio -1.03
- P/E Growth -1.03
- Net Income $-47,413,000
Income Statement
Quarterly
Annual
Latest News of CRIS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Coddling College Kids Makes Gen Z Mental Health Crisis Worse | Opinion
Colleges pamper students with therapy animals and safe spaces, fostering a culture of fragility. Embracing antifragility, universities should promote debate, teaching students to handle opposing opini...
By Newsweek | 1 day ago -
Chaotic Sydney train shutdown averted after eleventh hour crisis talks with union
Sydney's train network narrowly avoided a shutdown as the government agreed to run 24-hour services, meeting rail union demands. Talks led to the strike being called off, averting disruptions to all t...
By The Guardian | 1 day ago -
Biden urged to use clemency powers to tackle 'crisis' of US mass incarceration
Over 60 members of Congress urge President Biden to use his clemency powers to address mass incarceration issues before leaving office. They call for pardons or sentence commutations to rectify unfair...
By The Guardian | 2 days ago
